| Advancement in leishmaniasis diagnosis and therapeutics: An update D Kumari, S Perveen, R Sharma, K Singh European Journal of Pharmacology 910, 174436, 2021 | 50 | 2021 |
| Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance S Perveen, D Kumari, K Singh, R Sharma European Journal of Medicinal Chemistry 229, 114066, 2022 | 33 | 2022 |
| Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery S Perveen, R Sharma Biochemical Pharmacology 197, 114906, 2022 | 14 | 2022 |
| Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics S Mukherjee, S Perveen, A Negi, R Sharma Tuberculosis 140, 102340, 2023 | 8 | 2023 |
| COVID-19 diagnostics: Molecular biology to nanomaterials S Perveen, A Negi, V Gopalakrishnan, S Panda, V Sharma, R Sharma Clinica Chimica Acta 538, 139-156, 2023 | 8 | 2023 |
| Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid A Negi, S Perveen, R Gupta, PP Singh, R Sharma Journal of Medicinal Chemistry, 2024 | 2 | 2024 |
| Lung Microbiome: Friend or Foe of Mycobacterium tuberculosis S Perveen, R Sharma Microbiome in Inflammatory Lung Diseases, 207-226, 2022 | 1 | 2022 |
| Third Generation Solid Dispersion-Based Formulation of Novel Anti-Tubercular Agent Exhibited Improvement in Solubility, Dissolution and Biological Activity G Paudwal, R Dolkar, S Perveen, R Sharma, PP Singh, PN Gupta The AAPS Journal 26 (3), 52, 2024 | | 2024 |
| Identification of Chemical Scaffolds Targeting Drug-Resistant and Latent Mycobacterium tuberculosis through High-Throughput Whole-Cell Screening S Perveen, A Negi, S Saini, A Gangwar, R Sharma ACS Infectious Diseases, 2024 | | 2024 |
| Nanozymes for Bioimaging and Disease Diagnostics M Mahajan, S Perveen, R Sharma Nanozymes in Medicine, 81-106, 2023 | | 2023 |
